Lung cancer and the future of pathology

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 3, 2011, Pages 293-295

  Cagle, Philip T ^a,b   Dacie, Sanja ^c  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; EDITORIAL; GENETICS; HUMAN; LUNG TUMOR; MUTATION; PATHOLOGY; PERSONALIZED MEDICINE; TUMOR GENE;

ADENOCARCINOMA; GENES, NEOPLASM; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MUTATION; PATHOLOGY;

EID: 79952981004     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Walk EE. The role of pathologists in the era of personalized medicine. Arch Pathol Lab Med. 2009; 133(4): 605-610.
2. Aspinall M. Personalized medicine and pathology: friend or foe? Arch Pathol Lab Med. 2009; 133(4): 527-528.
3. Hess JL. What are we anyway?: the role of pathologists in the 21st century. Arch Pathol Lab Med. 2010; 134(10): 1424-1426.
4. Talbert ML, Ashwood ER, Brownlee NA, et al. Resident preparation for practice: a white paper from the College of American Pathologists and Association of Pathology Chairs. Arch Pathol Lab Med. 2009; 133(7): 1139-1147.
5. Cagle PT, Allen TC, Dacic S, et al. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med. 2011; 135(1): 110-116.
6. Cagle PT. The cytogenetics and molecular genetics of lung cancer: implications for pathologists. In: Rosen PP and Fechner RE, eds. Pathology Annual. Vol. 25, Part 2. East Norwalk, CT: Appleton & Lange, Inc; 1990: 317-329.
7. Cagle PT. Molecular pathology of lung cancer and its clinical relevance. In: Katzenstein A-L, Churg A, eds. The Lung: Current Concepts. Baltimore: Lippincott Williams & Wilkins; 1993: 134-44. Monographs in Pathology, vol 36.
8. Chirieac LR, Dacic S. Targeted therapies in lung cancer. Surg Pathol Clin. 2010; 3(1): 71-82.
9. 4-ALK non-small cell lung cancer. Eur J Cancer. 2010;46(10):1773-1780.
10. Francis H, Solomon B. The current status of targeted therapy for non-small cell lung cancer. Intern Med J. 2010; 40(9): 611-618
11. Yoshida T, Zhang G, Haura EB. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem Pharmacol. 2010; 80(5): 613-623.
12. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10): 947-957.
13. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363(18): 1693-1703.
14. Chilosi M, Murer B. Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy. Arch Pathol Lab Med. 2010; 134(1): 55-65.
15. Dacic S, Shuai Y, Yousem S, Ohori P, Nikiforova M. Clinicopathological predictors of ECFRIKRAS mutational status in primary lung adenocarcinomas. Mod Pathol. 2010; 23(2): 159-168.
16. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol. 2010; 5(4): 411-414.
17. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010; 5(4): 442-447.
18. Rossi A, Maione P, Bareschino MA, et al. The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making. Curr Med Chem. 2010; 17(11): 1030-1038.
19. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International multidisciplinary lung adenocarcinoma classification. J Thoracic Oncol. 2011; 6(2): 244-285.
20. Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of ECFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009; 15(9): 3023-3028.
21. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol. Diagn. 2010; 12(2): 169-176.
22. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ATK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010; 16(5): 1561-1571.
23. D'Angelo SP, Park B, Azzoli CG, et al. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. J Thorac Cardiovasc Surg. 2011; 141(2): 476-480.
24. Pirker R, Herth FJ, Kerr KM, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010; 5(10): 1706-1713.
25. Li K. Pathology and radiology beyond looking at pictures. Arch Pathol Lab Med. 2009; 133(4): 587-590.